Circulating miR-18a: a sensitive cancer screening biomarker in human cancer.
Circulating miR-18a: a sensitive cancer screening biomarker in human cancer.
复制标题
DOI：
--
复制
发表时间：
2014-05
期刊：
影响因子：
2.3
通讯作者：
S. Komatsu;D. Ichikawa;H. Takeshita;R. Morimura;S. Hirajima;M. Tsujiura;T. Kawaguchi;Mahito Miyamae;H. Nagata;H. Konishi;A. Shiozaki;E. Otsuji
中科院分区：
文献类型：
--
作者：
S. Komatsu;D. Ichikawa;H. Takeshita;R. Morimura;S. Hirajima;M. Tsujiura;T. Kawaguchi;Mahito Miyamae;H. Nagata;H. Konishi;A. Shiozaki;E. Otsuji
据报道，MicroRNA在血浆/血清中可稳定检测，并且由于与蛋白质如Argonaute-2和高密度脂蛋白结合或被分泌颗粒如外泌体包装而表现出对内源性核糖核酸酶活性的抗性。这些分泌颗粒包括特定的microRNA，可以作为细胞间递质发挥作用。这些发现可能会在循环microRNA用于癌症治疗方面开辟一个新的和有前途的领域。特别是位于潜在致癌的miR-17-92簇中的miR-18 a是在几种类型的癌症中高度表达的microRNA。食管癌（AUC=0.944）、胰腺癌（AUC =0.936）、肝细胞癌（AUC =0.881）、结直肠癌等癌症患者血浆/血清中miR-18 a浓度远高于健康志愿者。这些报告提供了证据，表明循环中的miR-18可能是下一代生物标志物，并有助于非侵入性液体活检中的癌症筛查，达到临床令人满意的灵敏度和特异性程度。
MicroRNAs have been reported to be stably detectable in plasma/serum and to exhibit resistance to endogenous ribonuclease activity because of binding to proteins such as Argonaute-2 and high-density lipoprotein, or being packed by secretory particles such as exosomes. These secretory particles include specific microRNAs and can function as intercellular transmitters. These findings could open-up a new and promising field in the use of circulating microRNAs for cancer treatment. In particular, miR-18a, which is located in the potentially oncogenic miR-17-92 cluster, is a highly expressed microRNAs in several types of cancers. The concentration of miR-18a in plasma/serum of patients with cancer such as esophageal (AUC=0.944), pancreatic (AUC=0.936), hepatocellular (AUC=0.881), colorectal and other types of cancers is much higher than that of healthy volunteers. Such reports provide evidence that circulating miR-18 might be a next-generation biomarker and contribute to cancer screening in non-invasive liquid biopsy, to a clinically-satisfactory degree of sensitivity and specificity.